Retinoids and Differentiation of Normal and Malignant Hematopoietic Cells

[1]  P. Fenaux,et al.  Retinoic Acid Syndrome , 1998, Drug safety.

[2]  S. Corey,et al.  Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid , 1997, Leukemia.

[3]  A. Zelent,et al.  RaRα1/RARα2-PML mRNA expression in acute promyelocytic leukemia cells : A molecular and laboratory-clinical correlative study , 1997 .

[4]  Mi-Ock Lee,et al.  Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP‐TF and their heterodimerization , 1997, The EMBO journal.

[5]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[6]  D. Mangelsdorf,et al.  Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. , 1997, Genes & development.

[7]  G. Duester.  Involvement of Alcohol Dehydrogenase, Short-Chain Dehydrogenase/Reductase, Aldehyde Dehydrogenase, and Cytochrome P450 in the Control of Retinoid Signaling by Activation of Retinoic Acid Synthesis† , 1996 .

[8]  Jacek Ostrowski,et al.  Two distinct actions of retinoid-receptor ligands , 1996, Nature.

[9]  E. Wattel,et al.  All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. , 1996, Leukemia.

[10]  J. L. Napoli.  Retinoic acid biosynthesis and metabolism , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  P. Chambon.  A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  K. Shudo,et al.  Successful Treatment of Relapse of Acute Promyelocytic Leukemia with a New Synthetic Retinoid, Am80 , 1996, Annals of Internal Medicine.

[13]  R. Speich,et al.  Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. , 1996, Leukemia.

[14]  E. Smeland,et al.  The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells. , 1996, Blood.

[15]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[16]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[17]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[18]  P. Fenaux,et al.  In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. , 1995, Leukemia.

[19]  H. Tsuda,et al.  Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. , 1995, International journal of hematology.

[20]  P. Fenaux,et al.  All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Stunnenberg,et al.  9-cis retinoic acid signaling: changing partners causes some excitement. , 1995, Genes & development.

[22]  M. Gaub,et al.  Characterization of nuclear retinoic acid binding activity in sensitive leukemic cell lines: cell specific uptake of ATRA and RAR alpha protein modulation. , 1995, Biochemical and Biophysical Research Communications - BBRC.

[23]  P. Chambon,et al.  Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. , 1995, Molecular endocrinology.

[24]  R. Warrell,et al.  9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. , 1995, Blood.

[25]  M. Donovan,et al.  The cellular retinoic acid binding proteins , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  K. Umesono,et al.  Unique response pathways are established by allosteric interactions among nuclear hormone receptors , 1995, Cell.

[27]  H. Dombret,et al.  All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. , 1995, Blood.

[28]  K. Umesono,et al.  LXR, a nuclear receptor that defines a distinct retinoid response pathway. , 1995, Genes & development.

[29]  J. Wiley,et al.  Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. , 1995, Leukemia.

[30]  T. Perlmann,et al.  A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. , 1995, Genes & development.

[31]  J. Gustafsson,et al.  OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Zelenetz,et al.  Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). , 1995, Blood.

[33]  C. Chastang,et al.  Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. , 1995, Leukemia & lymphoma.

[34]  S. Nagpal,et al.  Separation of Transactivation and AP1 Antagonism Functions of Retinoic Acid Receptor (*) , 1995, The Journal of Biological Chemistry.

[35]  P. Emanuel,et al.  A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. , 1994, The New England journal of medicine.

[36]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[37]  M. Toubert,et al.  Induction of high-affinity GM-CSF receptors during all-trans retinoic acid treatment of acute promyelocytic leukemia. , 1994, Leukemia.

[38]  P. Fenaux,et al.  Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. , 1994, Leukemia.

[39]  G. Zauli,et al.  All-trans retinoic acid and induction of apoptosis in acute promyelocytic leukemia cells. , 1994, Leukemia & lymphoma.

[40]  M. Fey,et al.  Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter] , 1994 .

[41]  M. Fey,et al.  Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group. , 1994, Blood.

[42]  R. Gallagher,et al.  Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-alpha. , 1994, Blood.

[43]  P Chambon,et al.  The retinoid signaling pathway: molecular and genetic analyses. , 1994, Seminars in cell biology.

[44]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[45]  N. Stuurman,et al.  The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.

[46]  A. Zelent.  TRANSLOCATION OF THE RARα LOCUS TO THE PML OR PLZF GENE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1994 .

[47]  E. Dmitrovsky,et al.  All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study , 1994, Annals of Internal Medicine.

[48]  V. Giguère.  Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. , 1994, Endocrine reviews.

[49]  A. Zelent,et al.  PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. Dejean,et al.  The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells , 1994 .

[51]  P. Martiat,et al.  Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. , 1994, Leukemia.

[52]  R. Evans,et al.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein , 1994, Cell.

[53]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[54]  N. Komatsu,et al.  Acute promyelocytic leukaemia, tretinoin, and granulocyte colony-stimulating factor , 1994, The Lancet.

[55]  H. Koeffler,et al.  Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. , 1993, Blood.

[56]  J. Pike,et al.  Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. , 1993, The Journal of biological chemistry.

[57]  H. Tilly,et al.  Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia , 1993 .

[58]  R. Krance,et al.  Tretinoin toxicity in children with acute promyelocytic leukaemia , 1993, The Lancet.

[59]  M. Kris,et al.  Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. , 1993, Journal of the National Cancer Institute.

[60]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[61]  T. Naoe,et al.  Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia , 1993 .

[62]  M. Villalona-Calero,et al.  Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF) , 1993, Leukemia.

[63]  P. Fenaux,et al.  Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. , 1993, Blood.

[64]  H. de Thé,et al.  PML protein expression in hematopoietic and acute promyelocytic leukemia cells. , 1993, Blood.

[65]  P. Pelicci,et al.  Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. , 1993, Blood.

[66]  Myriam Alcalay,et al.  The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.

[67]  P. Chambon,et al.  PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. , 1993, The EMBO journal.

[68]  C. Chomienne,et al.  Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. , 1993, Leukemia.

[69]  R. Warrell,et al.  Acute promyelocytic leukemia. , 1993, The New England journal of medicine.

[70]  Xiao-Kun Zhang,et al.  Regulation of retinoid and thyroid hormone action through homodimeric and heterodimeric receptors , 1993, Trends in Endocrinology & Metabolism.

[71]  R. Berger,et al.  Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. , 1993, The Journal of clinical investigation.

[72]  R. Berger,et al.  A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. , 1992, Leukemia.

[73]  R. Evans,et al.  A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. , 1992, Genes & development.

[74]  A. Näär,et al.  Transcriptional regulation by the nuclear receptor superfamily. , 1992, Current opinion in biotechnology.

[75]  H. Dombret,et al.  All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. , 1992, Blood.

[76]  K. Robertson,et al.  Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. , 1992, Blood.

[77]  J. L. Napoli,et al.  Biosynthesis of all-trans-retinoic acid from retinal. Recognition of retinal bound to cellular retinol binding protein (type I) as substrate by a purified cytosolic dehydrogenase. , 1992, The Journal of biological chemistry.

[78]  R. Warrell,et al.  The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.

[79]  T. Naoe,et al.  Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. , 1992, Leukemia.

[80]  C. Chomienne,et al.  Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. , 1992, Cancer research.

[81]  R. Warrell,et al.  Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.

[82]  F. Lo Coco,et al.  Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. , 1992, The EMBO journal.

[83]  P. Chambon,et al.  Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. , 1992, The EMBO journal.

[84]  L. Deaven,et al.  Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia , 1992, Molecular and cellular biology.

[85]  M. Pfahl,et al.  Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors , 1992, Nature.

[86]  Gregor Eichele,et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.

[87]  J. Grippo,et al.  9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.

[88]  E. Dmitrovsky,et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992, Blood.

[89]  A. Agadir,et al.  Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1991, Leukemia.

[90]  H. de Thé,et al.  All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. , 1991, The Journal of clinical investigation.

[91]  P. Freemont,et al.  Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. , 1991, Science.

[92]  J. Samarut,et al.  A novel mechanism of action for v-ErbA: Abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors , 1991, Cell.

[93]  J. L. Napoli,et al.  Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. , 1991, The Journal of biological chemistry.

[94]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[95]  K. Umesono,et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.

[96]  P. Pelicci,et al.  Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. , 1991, Oncogene.

[97]  J. L. Napoli,et al.  Holocellular retinol binding protein as a substrate for microsomal retinal synthesis. , 1991, Biochemistry.

[98]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[99]  P. Pandolfi,et al.  Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[100]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[101]  H. Dombret,et al.  Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid , 1990, The Lancet.

[102]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[103]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[104]  D. Sheer,et al.  Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. , 1990, Science.

[105]  S. Collins,et al.  Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha) , 1990, Molecular and cellular biology.

[106]  T G Cotter,et al.  HL‐60 cells induced to differentiate towards neutrophils subsequently die via apoptosis , 1990, Clinical and experimental immunology.

[107]  J. Testa.  Chromosome translocations in human cancer. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[108]  M. K. Armstrong,et al.  Cellular lipid binding proteins: expression, function, and nutritional regulation 1 , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  R. Berger,et al.  RETINOIC ACID THERAPY FOR PROMYELOCYTIC LEUKAEMIA , 1989, The Lancet.

[110]  W. Blaner.  Retinol-binding protein: the serum transport protein for vitamin A. , 1989, Endocrine reviews.

[111]  O. Gandrillon,et al.  Expression of the v-erbA product, an altered nuclear hormone receptor, is sufficient to transform erythrocytic cells in vitro , 1989, Cell.

[112]  R. Kurzrock,et al.  Malignancy-associated Sweet's syndrome: review of the world literature. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[114]  Z. Wang,et al.  All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. , 1987, Chinese medical journal.

[115]  A. Tobler,et al.  Retinoids. Structure-function relationship in normal and leukemic hematopoiesis in vitro. , 1986, The Journal of clinical investigation.

[116]  Koeffler Hp.  Human acute myeloid leukemia lines: models of leukemogenesis. , 1986 .

[117]  J. Fontana,et al.  The role of 13 cis‐retinoic acid in the remission induction of a patient with acute promyelocytic leukemia , 1986, Cancer.

[118]  J. Rowley,et al.  Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. , 1984, The American journal of medicine.

[119]  H. Koeffler,et al.  Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. , 1982, Experimental cell research.

[120]  S. Collins,et al.  Terminal Differentiation of Human Promyelocytic Leukemic Cells in Primary Culture in Response to Retinoic Acid , 1981 .

[121]  R. Lotan,et al.  Retinoic acid-induced modifications in the growth and cell surface components of a human carcinoma (HeLa) cell line. , 1980, Experimental cell research.

[122]  S. Collins,et al.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[123]  H. Gralnick,et al.  A variant form of hypergranular promyelocytic leukemia (M3) , 1980, Annals of internal medicine.

[124]  L. Ellman,et al.  Acute promyelocytic leukemia , 1979, American journal of hematology.

[125]  L. Sachs.  Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia , 1978, Nature.

[126]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[127]  R. Sweet.  AN ACUTE FEBRILE NEUTROPHTLIC DERMATOSTS. , 1964 .

[128]  P. Fenaux,et al.  All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.

[129]  L. Nagy,et al.  Retinoid-induced apoptosis in normal and neoplastic tissues , 1998, Cell Death and Differentiation.

[130]  E. Estey,et al.  A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia , 1997, Leukemia.

[131]  A. Baruchel,et al.  Chronic myelomonocytic leukemia: from biology to therapy. , 1997, Hematology and cell therapy.

[132]  H. Dombret,et al.  All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. , 1996, Leukemia.

[133]  A. Notario,et al.  Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. , 1996, Haematologica.

[134]  P. Rousselot,et al.  Récepteurs nucléaires et ontogénèse du tissu hématopoïétique. , 1995 .

[135]  P. Maslak,et al.  Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. , 1994, Leukemia.

[136]  H. Snoeck,et al.  Effect of retinoic acid (RA) on myeloid progenitors in normal bone marrow (BM) , 1994, Leukemia.

[137]  P. Fenaux,et al.  Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. , 1994, Blood.

[138]  C. Chomienne,et al.  In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. , 1994, Leukemia.

[139]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.

[140]  L. Sachs,et al.  45. Regulation of BcI-2 and cell death by all-trans retinoic acid in acute promyelocytic leukemic cells , 1992 .

[141]  Z. Wang,et al.  Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. , 1990, Nouvelle revue francaise d'hematologie.

[142]  J. Abita,et al.  Inefficacy of the synthetic aromatic retinoid etretinate and of its free acid on the in-vitro differentiation of leukemic cells. , 1986, Leukemia research.

[143]  J. Abita,et al.  Structure-activity relationships of aromatic retinoids on the differentiation of the human histiocytic lymphoma cell line U-937. , 1986, Leukemia research.

[144]  A. Kalamkarian,et al.  [Sweet's syndrome (acute febrile neutrophilic dermatosis)]. , 1985, Vestnik dermatologii i venerologii.